Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Metabolic tumor volume assessed by 18F FDG - PET CT scan as a predictive biomarker for immune checkpoint blockers in advanced NSCLC and its biological correlates.
Dall'Olio FG, Zrafi W, Roelants V, Ambrosini V, Fourquet A, Mitea C, Passiglia F, Bauckneht M, Bonardel G, Conci N, Benitez JC, Arena V, Namour C, Naigeon M, Monnet I, Beshiri K, Hoton D, Dursun S, Danlos FX, Argalia G, Aldea M, Rovera G, Derosa L, Iebba V, Gietema HA, Gounant V, Lacroix V, Remon J, Gautheret D, Chaput N, Job B, Kannouche PL, Velasco-Nuño M, Zitvogel L, Cella E, Chícharo de Freitas JR, Vasseur D, Bettaieb MA, Tagliamento M, Hendriks L, Italiano A, Planchard D, Marabelle A, Barlesi F, Novello S, De Andreis D, Aboubakar Nan F, Ardizzoni A, Zalcman G, Garcia C, Besse B. Dall'Olio FG, et al. Among authors: danlos fx. Clin Cancer Res. 2024 Oct 22. doi: 10.1158/1078-0432.CCR-24-1993. Online ahead of print. Clin Cancer Res. 2024. PMID: 39437011
Circulating Proteins Associated with Anti-IL6 Receptor Therapeutic Resistance in the Sera of Patients with Severe COVID-19.
Michot JM, Dozio V, Rohmer J, Pommeret F, Roumier M, Yu H, Sklodowki K, Danlos FX, Ouali K, Kishazi E, Naigeon M, Griscelli F, Gachot B, Groh M, Bacciarello G, Stoclin A, Willekens C, Sakkal M, Bayle A, Zitvogel L, Silvin A, Soria JC, Barlesi F, Beeler K, André F, Vasse M, Chaput N, Ackermann F, Escher C, Marabelle A. Michot JM, et al. Among authors: danlos fx. J Proteome Res. 2024 Nov 1;23(11):5001-5015. doi: 10.1021/acs.jproteome.2c00422. Epub 2024 Oct 1. J Proteome Res. 2024. PMID: 39352225
Is Local Ablative Stereotactic Radiation Therapy a Valuable Rescue Strategy for Time on Drug in Patients Enrolled in Phase I Trials?
Mavrikios A, Baldini C, Loriot Y, Hénon C, Marabelle A, Postel-Vinay S, Champiat S, Danlos FX, Quevrin C, Lopes E, Gazzah A, Bahleda R, Massard C, Deutsch E, Levy A. Mavrikios A, et al. Among authors: danlos fx. Int J Radiat Oncol Biol Phys. 2024 Dec 1;120(5):1245-1256. doi: 10.1016/j.ijrobp.2024.07.2336. Epub 2024 Aug 10. Int J Radiat Oncol Biol Phys. 2024. PMID: 39128580
Exploring the Role of Target Expression in Treatment Efficacy of Antibody-Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review.
Mathiot L, Baldini C, Letissier O, Hollebecque A, Bahleda R, Gazzah A, Smolenschi C, Sakkal M, Danlos FX, Henon C, Beshiri K, Goldschmidt V, Parisi C, Patrikidou A, Michot JM, Marabelle A, Postel-Vinay S, Bernard-Tessier A, Loriot Y, Ponce S, Champiat S, Ouali K. Mathiot L, et al. Among authors: danlos fx. Curr Oncol Rep. 2024 Oct;26(10):1236-1248. doi: 10.1007/s11912-024-01576-9. Epub 2024 Jul 27. Curr Oncol Rep. 2024. PMID: 39066847 Review.
Impact of Clonal Hematopoiesis-Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING Trial.
Rodriguez J, Baldini C, Bayle A, Pages A, Danlos FX, Vasseur D, Rouleau E, Lacroix L, Alonso de Castro B, Goldschmidt V, Seknazi L, Hollebecque A, Michot JM, Champiat S, Marabelle A, Ouali K, Marzac C, Ponce S, Micol JB, Chaput N, Massard C, Italiano A. Rodriguez J, et al. Among authors: danlos fx. JCO Precis Oncol. 2024 May;8:e2300631. doi: 10.1200/PO.23.00631. JCO Precis Oncol. 2024. PMID: 38815178 Clinical Trial.
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
Géraud A, Hueso T, Laparra A, Bige N, Ouali K, Cauquil C, Stoclin A, Danlos FX, Hollebecque A, Ribrag V, Gazzah A, Goldschmidt V, Baldini C, Suzzoni S, Bahleda R, Besse B, Barlesi F, Lambotte O, Massard C, Marabelle A, Castilla-Llorente C, Champiat S, Michot JM. Géraud A, et al. Among authors: danlos fx. Eur J Cancer. 2024 Jul;205:114075. doi: 10.1016/j.ejca.2024.114075. Epub 2024 May 4. Eur J Cancer. 2024. PMID: 38733717 Review.
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations.
Rached L, Laparra A, Sakkal M, Danlos FX, Barlesi F, Carbonnel F, De Martin E, Ducreux M, Even C, Le Pavec J, Michot JM, M Ribeiro J, Scotte F, Ponce Aix S, Lambotte O, Baldini C, Champiat S. Rached L, et al. Among authors: danlos fx. Cancer Treat Rev. 2024 Jun;127:102751. doi: 10.1016/j.ctrv.2024.102751. Epub 2024 May 4. Cancer Treat Rev. 2024. PMID: 38729086 Free article. Review.
68 results